International development

The LFB Group currently generates nearly 30% of its turnover from international business, and LFB biomedicines are present in more than 40 countries.

LFB Biopharmaceuticals is one of the LFB group’s active subsidiaries in Europe, along with LFB GmbH in Germany.

LFB’s international development relies on an active registration policy for high-potential biomedicines, allowing rapid commercial growth, alongside the opening of subsidiaries.